Every day represents an opportunity to alter the course of relentlessly progressive neurodegenerative diseases and the people they affect–and a responsibility to support and potentially improve the lives of people, families, and communities around the world.
There is still much to learn about ALS, and R&D is a critical pillar of how we’ll deliver on our mission to one day end the suffering caused by neurodegenerative diseases.
Learn more about our commitment to research in ALS: amylyx.com/ALS
Hover over Tap for more information including regional details.
Progressive supranuclear palsy (PSP) is a rare, progressive, and adult-onset neurological disorder that affects walking and balance, eye movement, swallowing, and speech. People living with PSP have a life expectancy of six to eight years after initial diagnosis, and the epidemiology of PSP is similar to that of ALS. PSP is characterized by abnormal tau inclusions and is consequently also known as a tauopathy.
Learn more about our research in PSP: amylyx.com/PSP
Hover over Tap for more information including regional details.
Wolfram syndrome (WS) is an autosomal recessive neurodegenerative disease characterized by juvenile onset diabetes mellitus, optic nerve atrophy, deafness, and diabetes insipdius. WS is considered a prototypical endoplasmic reticulum (ER) stress disorder. The prognosis of WS is poor, and many people with the disease die prematurely with severe neurological disabilities.
Hover over Tap for more information including regional details.
Alzheimer’s Disease is a relentlessly progressive disease affecting the memories, thoughts and behavior of millions of people worldwide. Through our research, we aim to further characterize the biological activity of our candidates to inform potential clinical development.
Hover over Tap for more information including regional details.
Stay informed
Click subscribe to receive updates and corporate announcements from Amylyx.